✨
AI Summary & Key Takeaways
AI Insight⚡ TL;DR(Too Long; Didn't Read)
It may be feasible to assess the effect of mitochondrial-targeted drugs to treat sarcopenia in patients with chronic kidney disease.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Uremic toxins contribute to the impairment of mitochondrial function that subsequently could result in organ failure.
📊
Key Findings & Data:Mitochondrial dysfunction also plays an essential role in the pathogenesis of sarcopenia in chronic kidney disease patients.
💡
Conclusion & Impact:It may be feasible to assess the effect of mitochondrial-targeted drugs to treat sarcopenia in patients with chronic kidney disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Uremic toxins contribute to the impairment of mitochondrial function that subsequently could result in organ failure. Mitochondrial dysfunction also plays an essential role in the pathogenesis of sarcopenia in chronic kidney disease patients. It may be feasible to assess the effect of mitochondrial-targeted drugs to treat sarcopenia in patients with chronic kidney disease.
🔖
Cite This Article
İKİZLER, T. A., YILDIZ, A. (2022). The Frailty of Advanced Kidney Disease: The Role of Mitochondria. Turkish journal of nephrology (Online), Cilt: 31 - Sayı: 3, 190–193. https://ajindex.com/articles/612809